PTC844 for Rheumatoid Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to placebo in participants with active rheumatoid arthritis (RA).
Are You a Good Fit for This Trial?
This trial is for adults with active rheumatoid arthritis who have either never used or did not respond well to standard RA treatments. Their disease must be moderately active or worse, and their current medications should be stable before joining.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- PTC844
Trial Overview
The study compares a new drug called PTC844 to a placebo in people with active rheumatoid arthritis. It looks at safety, how the body processes the drug, and its effects on certain biological markers.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive PTC844 at a low dose once daily (QD) orally for 12 weeks.
Participants will receive PTC844 at a high dose QD orally for 12 weeks.
Participants will receive placebo matching to PTC844 QD orally for 12 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
PTC Therapeutics
Lead Sponsor
Dr. Matthew B. Klein
PTC Therapeutics
Chief Executive Officer since 2023
BA from the University of Pennsylvania, MD from Yale University School of Medicine, MS in Epidemiology from the University of Washington School of Public Health
Dr. Stuart W. Peltz
PTC Therapeutics
Chief Medical Officer since 2023
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.